Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376202 | 0.93 | BRD4 (0.47) | BRD4 | |
| SCHEMBL2375778 | 0.92 | JAK2 (0.40) | JAK2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2377819 | 0.90 | JAK2 (0.42) | JAK2HDAC3HDAC1HDAC2BRD4 | |
| SCHEMBL2378940 | 0.90 | KDM4E (0.43) | BRD4 | |
| SCHEMBL2377327 | 0.90 | BRD4 (0.42) | BRD4 | |
| SCHEMBL2377720 | 0.89 | JAK2 (0.54) | JAK2JAK3 | |
| SCHEMBL2377187 | 0.89 | JAK2 (0.43) | JAK2JAK3 | |
| Hydrochloric Acid SCHEMBL2377276 | 0.87 | MAPK1 (0.37) | HDAC3HDAC1HDAC2BRD4 | |
| SCHEMBL2377365 | 0.87 | JAK2 (0.39) | JAK2JAK3 | |
| SCHEMBL2378719 | 0.87 | KDM4E (0.39) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102232076-A | Pyrrolopyrazinyl urea kinase inhibitors | HOFFMANN LA ROCHE | 2011-11-02 | — | — | CN | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | JAK2 5/4885HDAC3 1561/4885HDAC1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.